Danish clinical-stage radiopharmaceuticals company Curasight A/S (Spotlight: CURAS) on Wednesday reported continued progress in its Phase 2 study of the diagnostic platform uTRACE in prostate cancer.

All nine clinical sites in Germany, Sweden, and Denmark are now fully activated and recruiting patients, following completion of part 1 earlier in 2025.

The study forms part of a strategic collaboration between Curasight and France-based nuclear medicine company Curium Inc., established in May 2023. Under the agreement, Curasight may receive up to USD70m in milestone payments and double-digit royalties on future commercial sales of uTRACE.

The Phase 2 trial assesses Curasight's PET tracer, 64Cu-DOTA-AE105 (uTRACE), as a tool to grade tumour aggressiveness in prostate cancer patients under active surveillance. The study aims to improve differentiation between indolent and aggressive disease, potentially reducing overtreatment and enhancing patient outcomes.

Curasight said recruitment in part 2 of the trial is progressing well, with completion expected in the first half of 2026.

In addition to the prostate cancer programme, Curasight plans to initiate a Phase 1 trial of its therapeutic platform uTREAT in brain cancer later this quarter.